Prevention and treatment of hepatitis C virus recurrence after liver transplantation

Journal of Hepatology

Volumn 41, Issue 1, 2004, Pages 2-10

  Garcia Retortillo, Montserrat ^a   Forns, Xavier ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

HYPERIMMUNE GLOBULIN; IMMUNOSUPPRESSIVE AGENT; PEGINTERFERON ALPHA2B; RIBAVIRIN;

CHRONIC HEPATITIS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EARLY DIAGNOSIS; ERADICATION THERAPY; GENETIC HETEROGENEITY; GRAFT REJECTION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOPROPHYLAXIS; INFECTION PREVENTION; INFECTION RISK; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER GRAFT; PRIORITY JOURNAL; RECURRENT DISEASE; SHORT SURVEY; SIDE EFFECT; VIRUS LOAD; VIRUS NEUTRALIZATION;

EID: 3442898180     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2004.04.023     Document Type: Review

References (65)

1. Adam R., McMaster P., O'Grady J.G., Castaing D., Klempnauer J.L., Jamieson N., et al. Evolution of liver transplantation in Europe: report of the European Liver Transplant Registry. Liver Transpl. 9:2003;1231-1243
2. Garcia-Retortillo M., Forns X., Feliu A., Moitinho E., Costa J., Navasa M., et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology. 35:2002;680-687
3. Berenguer M., Lopez-Labrador F.X., Wright T.L. Hepatitis C and liver transplantation. J Hepatol. 35:2001;666-678
4. Prieto M., Berenguer M., Rayon J.M., Cordoba J., Arguello L., Carrasco D., et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology. 29:1999;250-256
5. Berenguer M., Prieto M., Rayon J.M., Mora J., Pastor M., Ortiz V., et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology. 32:2000;852-858
6. Forman L.M., Lewis J.D., Berlin J.A., Feldman H.I., Lucey M.R. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology. 122:2002;889-896
7. Berenguer M., Prieto M., Cordoba J., Rayon J.M., Carrasco D., Olaso V., et al. Early development of chronic active hepatitis in recurrent hepatitis C virus infection after liver transplantation: association with treatment of rejection. J Hepatol. 28:1998;756-763
8. Berenguer M., Ferrell L., Watson J., Prieto M., Kim M., Rayon M., et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol. 32:2000;673-684
9. Berenguer M., Prieto M., San Juan F., Rayon J.M., Martinez F., Carrasco D., et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology. 36:2002;202-210
10. Berenguer M. Host and donor risk factors before and after liver transplantation that impact HCV recurrence. Liver Transpl. 9:2003;S44-S47
11. Gretch D.R., Polyak S.J., Wilson J.J., Carithers R.L. Jr, Perkins J.D., Corey L. Tracking hepatitis C virus quasispecies major and minor variants in symptomatic and asymptomatic liver transplant recipients. J Virol. 70:1996;7622-7631
12. Pelletier S.J., Raymond D.P., Crabtree T.D., Iezzoni J.C., Sawyer R.G., Hahn Y.S., et al. Pretransplantation hepatitis C virus quasispecies may be predictive of outcome after liver transplantation. Hepatology. 32:2000;375-381
13. Pelletier S.J., Raymond D.P., Crabtree T.D., Berg C.L., Iezzoni J.C., Hahn Y.S., et al. Hepatitis C-induced hepatic allograft injury is associated with a pretransplantation elevated viral replication rate. Hepatology. 32:2000;418-426
14. Rosen H.R., Chou S., Corless C.L., Gretch D.R., Flora K.D., Boudousquie A., et al. Cytomegalovirus viremia: risk factor for allograft cirrhosis after liver transplantation for hepatitis C. Transplantation. 64:1997;721-726
15. Berenguer M., Crippin J., Gish R., Bass N., Bostrom A., Netto G., et al. A model to predict severe HCV-related disease following liver transplantation. Hepatology. 38:2003;34-41
16. Crippin J.S., McCashland T., Terrault N., Sheiner P., Charlton M.R. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl. 8:2002;350-355
17. Everson G., Trouillot T., Trotter J., Halprin A., McKinley C., Fey B. Treatment of decompensated cirrhotics with a low-accelerating dose regimen (LADR) of interferon-alfa-2b plus ribavirin: safety and efficacy. Hepatology (Abstract). 32:2001;595
18. Forns X., Garcia-Retortillo M., Serrano T., Feliu A., Suarez F., de la Mata M., et al. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol. 39:2003;389-396
19. Villamil F.G. Prophylaxis with anti-HBs immune globulins and nucleoside analogues after liver transplantation for HBV infection. J Hepatol. 39:2003;466-474
20. Bukh J., Forns X., Emerson S.U., Purcell R.H. Studies of hepatitis C virus in chimpanzees and their importance for vaccine development. Intervirology. 44:2001;132-142
21. Forns X., Purcell R.H., Bukh J. Quasispecies in viral persistence and pathogenesis of hepatitis C virus. Trends Microbiol. 7:1999;402-410
22. Farci P., Shimoda A., Wong D., Cabezon T., De Gioannis D., Strazzera A., et al. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci USA. 93:1996;15394-15399
23. Krawczynski K. Passive transfer of anti-HCV in chronic and acute HCV infection in chimpanzees - trials of experimental immune treatment. Hepatology (Abstract). 30:1999;423A
24. Feray C., Gigou M., Samuel D., Ducot B., Maisonneuve P., Reynes M., et al. Incidence of hepatitis C in patients receiving different preparations of hepatitis B immunoglobulins after liver transplantation. Ann Intern Med. 128:1998;810-816
25. Willems B., Ede M., Marotta P., Wall W., Greig P., Lilly L., et al. Anti-HCV human immunoglobulins for the prevention of graft infection in HCV-related liver transplantation, a pilot study. J Hepatol (Abstract). 36:2002;32
26. Agnello V., Abel G., Elfahal M., Knight G.B., Zhang Q.X. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci USA. 96:1999;12766-12771
27. Pileri P., Uematsu Y., Campagnoli S., Galli G., Falugi F., Petracca R., et al. Binding of hepatitis C virus to CD81. Science. 282:1998;938-941
28. Bartosch B., Bukh J., Meunier J.C., Granier C., Engle R.E., Blackwelder W.C., et al. In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes. Proc Natl Acad Sci USA. 100:2003;14199-14204
29. Licata A., Di Bona D., Schepis F., Shahied L., Craxi A., Camma C. When and how to treat acute hepatitis C? J Hepatol. 39:2003;1056-1062
30. Feray C., Samuel D., Gigou M., Paradis V., David M.F., Lemonnier C., et al. An open trial of interferon alfa recombinant for hepatitis C after liver transplantation: antiviral effects and risk of rejection. Hepatology. 22:1995;1084-1089
31. Singh N., Gayowski T., Wannstedt C.F., Shakil A.O., Wagener M.M., Fung J.J., et al. Interferon-alpha for prophylaxis of recurrent viral hepatitis C in liver transplant recipients: a prospective, randomized, controlled trial. Transplantation. 65:1998;82-86
32. Sheiner P.A., Boros P., Klion F.M., Thung S.N., Schluger L.K., Lau J.Y., et al. The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation. Hepatology. 28:1998;831-838
33. Mazzaferro V., Schiavo M., Caccamo L., Tagger A., Morabio A., Lavezzo B. Prospective randomized trial on early treatment of HCV infection after liver transplantation in HCV-RNA positive patients. Liver Transpl (Abstract). 9:2003;C-36
34. Terrault N., Khalili M., Straley S., Bollinger K., Bass N., Roberts J., Ascher N. Efficacy an tolerability of preemtive interferon (IFN) versus interferon plus ribavirin (RBV) treatment in hepatitis C virus (HCV) infected liver transplant recipients. Hepatology (Abstract). 38:2004;158A
35. Bizollon T., Palazzo U., Ducerf C., Chevallier M., Elliott M., Baulieux J., et al. Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation. Hepatology. 26:1997;500-504
36. Firpi R.J., Abdelmalek M.F., Soldevila-Pico C., Reed A., Hemming A., Howard R., et al. Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C. Liver Transpl. 8:2002;1000-1006
37. Lavezzo B., Franchello A., Smedile A., David E., Barbui A., Torrani M., et al. Treatment of recurrent hepatitis C in liver transplants: efficacy of a six versus a twelve month course of interferon alfa 2b with ribavirin. J Hepatol. 37:2002;247-252
38. Shakil A.O., McGuire B., Crippin J.S., Teperman L., Demetris A.J., Conjeevaran H., et al. A pilot study of interferon alfa and ribavirin combination in liver transplant recipients with recurrent hepatitis C. Hepatology. 36:2002;1253-1258
39. De Vera M.E., Smallwood G.A., Rosado K., Davis L., Martinez E., Sharma S., et al. Interferon-alpha and ribavirin for the treatment of recurrent hepatitis C after liver transplantation. Transplantation. 71:2001;678-686
40. Ahmad J., Dodson S.F., Demetris A.J., Fung J.J., Shakil A.O. Recurrent hepatitis C after liver transplantation: a nonrandomized trial of interferon alfa alone versus interferon alfa and ribavirin. Liver Transpl. 7:2001;863-869
41. Dumortier J., Scoazec J.Y., Chevallier P., Boillot O. Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination. J Hepatol. 40:2004;669-674
42. Kugelmas M., Osgood M.J., Trotter J.F., Bak T., Wachs M., Forman L., et al. Hepatitis C virus therapy, hepatocyte drug metabolism, and risk for acute cellular rejection. Liver Transpl. 9:2003;1159-1165
43. Samuel D., Bizollon T., Feray C., Roche B., Ahmed S.N., Lemonnier C., et al. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology. 124:2003;642-650
44. Samuel D., Brousse P. Treatment of patients with recurrent hepatitis C after liver transplantation with pegylated intereron and ribavirin. Hepatology (Abstract). 34:2004;531A
45. Neumann A.U., Langrher J., Berg T., Neuhaus P. Treatment of recurrent hepatitis C after liver transplantation with peginterferon alfa-2b and ribavirin. Hepatology (Abstract). 34:2004;531A
46. Rodriguez-Luna H., Khatib A., Sharma P., De Petris G., Williams J.W., Ortiz J., et al. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: an open-label series. Transplantation. 77:2004;190-194
47. Poynard T., McHutchison J., Davis G.L., Esteban-Mur R., Goodman Z., Bedossa P., et al. Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology. 32:2000;1131-1137
48. Poynard T., McHutchison J., Manns M., Trepo C., Lindsay K., Goodman Z., et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology. 122:2002;1303-1313
49. Camma C., Di Bona D., Schepis F., Heathcote E.J., Zeuzem S., Pockros P.J., et al. Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data. Hepatology. 39:2004;333-342
50. Bizollon T., Ahmed S.N., Radenne S., Chevallier M., Chevallier P., Parvaz P., et al. Long term histological improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrence. Gut. 52:2003;283-287
51. Alberti A.B., Belli L.S., Airoldi A., de Carlis L., Rondinara G., Minola E., et al. Combined therapy with interferon and low-dose ribavirin in posttransplantation recurrent hepatitis C: a pragmatic study. Liver Transpl. 7:2001;870-876
52. Abdelmalek M.F., Firpi R.J., Soldevila-Pico C., Reed A.I., Hemming A.W., Liu C., et al. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C. Liver Transpl. 10:2004;199-207
53. Lohmann V., Korner F., Koch J., Herian U., Theilmann L., Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science. 285:1999;110-113
54. Love R.A., Parge H.E., Wickersham J.A., Hostomsky Z., Habuka N., Moomaw E.W., et al. The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site. Cell. 87:1996;331-342
55. Lamarre D., Anderson P.C., Bailey M., Beaulieu P., Bolger G., Bonneau P., et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature. 426:2003;186-189
56. Hinrichsen H., Benhamou Y., Resier M., Sentjens R., Wedemeyer H., Calleja J., et al. First report on the antiviral efficacy of BILN 2061, a novel oral HCV serine protease inhibitor, in patients with chronic genotype 1 hepatitis C infection and minimal liver fibrosis. Hepatology. 36:2002;145A. (Abstract)
57. Forns X., Bataller R. Can we identify liver fibrosis in HCV-infected patients without a liver biopsy. Curr Hepat Rep. 2:2003;145-151
58. Friedman S.L. Liver fibrosis - from bench to bedside. J Hepatol. 38:2003;S38-S53
59. Burrell L.M., Farina N.K., Balding L.C., Johnston C.I. Beneficial renal and cardiac effects of vasopeptidase inhibition with S21402 in heart failure. Hypertension. 36:2000;1105-1111
60. Cao Z., Cooper M.E., Wu L.L., Cox A.J., Jandeleit-Dahm K., Kelly D.J., et al. Blockade of the renin-angiotensin and endothelin systems on progressive renal injury. Hypertension. 36:2000;561-568
61. Lewis E.J., Hunsicker L.G., Clarke W.R., Berl T., Pohl M.A., Lewis J.B., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 345:2001;851-860
62. Bataller R., Sancho-Bru P., Gines P., Lora J.M., Al Garawi A., Sole M., et al. Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II. Gastroenterology. 125:2003;117-125
63. Paizis G., Cooper M.E., Schembri J.M., Tikellis C., Burrell L.M., Angus P.W. Up-regulation of components of the renin-angiotensin system in the bile duct-ligated rat liver. Gastroenterology. 123:2002;1667-1676
64. Terui Y., Saito T., Watanabe H., Togashi H., Kawata S., Kamada Y., et al. Effect of angiotensin receptor antagonist on liver fibrosis in early stages of chronic hepatitis C. Hepatology. 36:2002;1022
65. Rimola A., Guevara G., Londoño M., Navasa M., Forns X., Garcia-Retortillo M. Beneficial effect of drugs interfering with the renin-angiotensin system on the development of fibrosis in hepatitis C recurrence after liver transplantation (LT). Transplantation. 2004;. in press